HbA1c may be the most effective method to identify patients with undiagnosed prediabetes and diabetes, and point-of-care testing further enhances that screening ability in primary-care settings, new research suggests. The findings were published recently in the Annals of Family Medicine by Heather P Whitley, PharmD, of Auburn University Harrison School of Pharmacy, Montgomery, Alabama, and colleagues. “First, diabetes and prediabetes need to be on our radar as possible diagnoses. In the United States, where we have such a heavy prevalence of diabetes, we need to be thoughtful and aggressive in screening,” And, for screening purposes, the data suggest that HbA1c is a better test than is a fasting blood glucose because postmeal glucose spikes happen sooner in the course of developing type 2 diabetes than does a high fasting. And, not surprisingly, use of a point-of-care HbA1c machine enabled detection of prediabetes and diabetes cases in a timelier manner compared with use of an outside lab. Ann Fam Med. 2017;15:162-164. Abstract
- Lyon, April 26, 2018. Dianax WINNER of BIGBOOSTER Class of 2018
- Milan, March 20, 2018. Dianax featured in “Platinum Aziende e Protagonisti”.
- Milan, November 16, 2017. Home Healthcare Market worth 365 Billion USD by 2022. Rising incidence of chronic diseases, testing, screening and monitoring new technologies to drive market growth.
- Lyon, November 16, 2017. dianax among the TOP WINNERS of BIGBOOSTER camp in Lyon and QUALIFIED for the next round!
- Milan, November 03, 2017. Europe POCT Market to reach almost USD 12 billion by 2024 – Emerging Microfluidic Lab-on-a-Chip Technology.